Misplaced Pages

Leriglitazone

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Leriglitazone
Clinical data
Other namesHydroxypioglitazone
ATC code
Identifiers
IUPAC name
  • 5-ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20N2O4S
Molar mass372.44 g·mol
3D model (JSmol)
SMILES
  • CC(C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3)O
InChI
  • InChI=1S/C19H20N2O4S/c1-12(22)14-4-5-15(20-11-14)8-9-25-16-6-2-13(3-7-16)10-17-18(23)21-19(24)26-17/h2-7,11-12,17,22H,8-10H2,1H3,(H,21,23,24)
  • Key:OXVFDZYQLGRLCD-UHFFFAOYSA-N

Leriglitazone is a PPAR-gamma agonist and metabolite of the glitazone pioglitazone. It is developed for adrenomyeloneuropathy, and other neurodegenerative diseases.

Society and culture

Legal status

In January 2024, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for leriglitazone (Nezglyal) requested by Minoryx Therapeutics S.L. In May 2024, the EMA confirmed its recommendation to refuse marketing authorization for leriglitazone. Leriglitazone was intended for the treatment of cerebral adrenoleukodystrophy.

References

  1. Musokhranova, Uliana; Grau, Cristina; Vergara, Cristina; Rodríguez-Pascau, Laura; Xiol, Clara; Castells, Alba A.; Alcántara, Soledad; Rodríguez-Pombo, Pilar; Pizcueta, Pilar; Martinell, Marc; García-Cazorla, Angels; Oyarzábal, Alfonso (26 October 2023). "Mitochondrial modulation with leriglitazone as a potential treatment for Rett syndrome". Journal of Translational Medicine. 21 (1): 756. doi:10.1186/s12967-023-04622-5. ISSN 1479-5876. PMC 10601217. PMID 37884937.
  2. Pizcueta, Pilar; Vergara, Cristina; Emanuele, Marco; Vilalta, Anna; Rodríguez-Pascau, Laura; Martinell, Marc (6 February 2023). "Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate". International Journal of Molecular Sciences. 24 (4): 3201. doi:10.3390/ijms24043201. ISSN 1422-0067. PMC 9961553. PMID 36834611.
  3. Rodríguez-Pascau, Laura; Vilalta, Anna; Cerrada, Marc; Traver, Estefania; Forss-Petter, Sonja; Weinhofer, Isabelle; Bauer, Jan; Kemp, Stephan; Pina, Guillem; Pascual, Sílvia; Meya, Uwe; Musolino, Patricia L.; Berger, Johannes; Martinell, Marc; Pizcueta, Pilar (2 June 2021). "The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy". Science Translational Medicine. 13 (596). doi:10.1126/scitranslmed.abc0555. PMID 34078742. S2CID 235305143.
  4. Pandolfo, Massimo; Reetz, Kathrin; Darling, Alejandra; Rodriguez de Rivera, Francisco Javier; Henry, Pierre-Gilles; Joers, James; Lenglet, Christophe; Adanyeguh, Isaac; Deelchand, Dinesh; Mochel, Fanny; Pousset, Françoise; Pascual, Sílvia; Van den Eede, Delphine; Martin-Ugarte, Itziar; Vilà-Brau, Anna; Mantilla, Adriana; Pascual, María; Martinell, Marc; Meya, Uwe; Durr, Alexandra (December 2022). "Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES)". Neurology: Genetics. 8 (6): e200034. doi:10.1212/NXG.0000000000200034. PMC 9747094. PMID 36524101.
  5. ^ "Nezglyal EPAR". European Medicines Agency. 25 January 2024. Retrieved 3 February 2024.
Other alimentary tract and metabolism products (A16)
Amino acids and derivatives
Enzymes
Other
Portal:


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Leriglitazone Add topic